Assessment in Work Productivity and the Relationship With Cognitive Symptoms in Patients With MDD Taking Vortioxetine

Major Depressive Disorder Clinical Trial

— AtWoRC  

Official title:

Interventional, Open-Label, Single Cohort, Canadian Study to Describe the Relationship Between Cognitive Symptoms and Work Productivity in Working Adults Treated With Vortioxetine for Major Depressive Disorder (MDD)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02332954
• Other study ID #: 15913A
• Status: Completed
• Phase: Phase 4
• First received: January 5, 2015
• Last updated: January 26, 2018
• Start date: February 2015
• Est. completion date: July 6, 2017

Study information

• Verified date: January 2018
• Source: Lundbeck Canada Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to describe the association/correlation between change in patient-reported cognitive symptoms and work productivity in gainfully employed patients receiving vortioxetine for a Major Depressive Episode (MDE).

Description:

This is an interventional, Canadian, multi-site, open-label, single cohort, flexible-dose study. The study will emulate a naturalistic real-life setting. Investigators will include Primary Care Physicians and Psychiatrists working in outpatient clinics. The study will include adult patients diagnosed with MDD according to the DSM-5™. Approximately 200 patients will be enrolled in the study. There will be approximately 100 patients who receive vortioxetine as a first treatment for the current MDE and 100 patients switched to vortioxetine due to inadequate response to their current antidepressant medication treatment. All patients will be treated with vortioxetine as per the product monograph, and at the doses determined appropriate by the investigator. The total study duration from Baseline to the end of follow-up will be approximately 56 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 226
• Est. completion date: July 6, 2017
• Est. primary completion date: July 6, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• The patient is a man or woman, aged =18 years and <65 years (In the province of British Columbia, the patient must be aged 19 years or older in order to give Informed Consent)

• The patient is engaged in volunteer work or gainful employment (working =20 hours per week) or is enrolled full-time in post-secondary studies or vocational training.

• The patient is an outpatient consulting a Primary Care Physician or a Psychiatrist.

• Patients must have a diagnosis of MDD according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5™) classification code 296.3x.

• The current MDE is confirmed by the investigator.

• The reported duration of the current MDE is at least 3 months.

• The patient has a Baseline score =15 on the QIDS-SR.

• The patient reports at least a minimal level of cognitive symptoms as defined by Baseline score of =30 on the PDQ-D-20.

• The patient is capable of communicating with the site personnel and is able to conduct the digit-symbol substitution test (DSST).

Exclusion Criteria:

• The patient score is >69 on the DSST at Screening/Baseline.

• The patient is, in the opinion of the investigator, not able to complete all the study assessments including, but not limited to, patient-reported assessments and the DSST.

• The patient has a current diagnosis or history of manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features.

• The current depressive symptoms are considered by the investigator to have been resistant to 2 adequate antidepressant treatments of at least 6 weeks duration each at the maximum recommended dose (according to Canadian labeling).

Other protocol defined inclusion and exclusion criteria do apply.

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Major
• Major Depressive Disorder
• Neurobehavioral Manifestations

Intervention

Drug:
• vortioxetine
The starting and recommended dose of vortioxetine is 10 mg once daily; film-coated 10 mg tablets for oral use once daily for 52 weeks.Depending on individual patient response, the dose may be increased to a maximum of 20 mg daily.

Locations

Country	Name	City	State
Canada	CA016	Burlington	Ontario
Canada	CA013	Chatham	Ontario
Canada	CA010	Corunna	Ontario
Canada	CA004	Edmonton	Alberta
Canada	CA012	Fort Erie	Ontario
Canada	CA007	Halifax	Nova Scotia
Canada	CA017	Hamilton	Ontario
Canada	CA026	Hamilton	Ontario
Canada	CA005	Kelowna	British Columbia
Canada	CA011	London	Ontario
Canada	CA003	Mississauga	Ontario
Canada	CA020	Montreal	Quebec
Canada	CA022	Montreal	Quebec
Canada	CA023	Montreal	Quebec
Canada	CA018	Pointe-Claire	Quebec
Canada	CA019	Quebec
Canada	CA021	Quebec
Canada	CA029	Quebec
Canada	CA008	Sarnia	Ontario
Canada	CA009	Sarnia	Ontario
Canada	CA028	Saskatoon	Saskatchewan
Canada	CA024	St-Jean-sur-Richelieu	Quebec
Canada	CA015	St. Catharines	Ontario
Canada	CA006	St. John's	Newfoundland and Labrador
Canada	CA030	Victoriaville	Quebec
Canada	CA027	Westmount	Quebec

Sponsors (1)

Lead Sponsor	Collaborator
Lundbeck Canada Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	the association/correlation between changes in patient-reported cognitive symptoms and work productivity. (Perceived Deficit Questionnaire-Depression)	Mean change from Baseline to Week 12 in patient-reported cognitive symptoms as measured by Perceived Deficit Questionnaire-Depression-20 questions (PDQ-D-20) and work productivity as measured by Work Limitations Questionnaire (WLQ) in gainfully employed patients receiving vortioxetine for a Major Depressive Episode (MDE).	12 weeks
Secondary	Cognitive function (PDQ-D-20)	Mean change from baseline in cognitive symptoms as measured by PDQ-D-20.	12 and 52 weeks
Secondary	Cognitive function (Digit Symbol Substitution Test (DSST)	Mean change from baseline in cognitive symptoms as measured by Digit Symbol Substitution Test (DSST).	12 and 52 weeks
Secondary	Work productivity (WLQ)	mean change from baseline in work productivity as measured by WLQ.	12 and 52 weeks
Secondary	Work productivity (Work Productivity and Activity Impairment (WPAI) questionnaire)	mean change from baseline in work productivity as measured by Work Productivity and Activity Impairment (WPAI) questionnaire.	12 and 52 weeks
Secondary	Work productivity (World Health Organization Disability Assessment Schedule-12 questions (WHODAS-12)	mean change from baseline in work productivity as measured by World Health Organization Disability Assessment Schedule-12 questions (WHODAS-12).	12 and 52 weeks
Secondary	Work productivity (Sheehan Disability Scale (SDS)	mean change from baseline in work productivity as measured by Sheehan Disability Scale (SDS).	12 and 52 weeks
Secondary	Depressive symptoms (Quick Inventory of Depression Symptomatology-Self Report (QIDS-SR)	mean change from baseline in depressive symptoms as measured by Quick Inventory of Depression Symptomatology-Self Report (QIDS-SR).	12 and 52 weeks
Secondary	Depressive symptoms (Clinical Global Impression-Improvement (CGI-I) score)	mean change in depressive symptoms as measured by Clinical Global Impression-Improvement (CGI-I) score.	12 and 52 weeks
Secondary	Depressive symptoms (Clinical Global Impression-Severity (CGI-S)	mean change from baseline in depressive symptoms as measured by Clinical Global Impression-Severity (CGI-S).	12 and 52 weeks